Provided by Tiger Fintech (Singapore) Pte. Ltd.

Veracyte

31.51
+1.083.55%
Post-market: 31.510.00000.00%16:23 EDT
Volume:679.72K
Turnover:21.41M
Market Cap:2.46B
PE:101.65
High:31.90
Open:30.84
Low:30.74
Close:30.43
Loading ...

Company Profile

Company Name:
Veracyte
Exchange:
NASDAQ
Establishment Date:
2006
Employees:
824
Office Location:
6000 Shoreline Court,Suite 300,South San Francisco,California,United States
Zip Code:
94080
Fax:
650 243 6388
Introduction:
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Directors

Name
Position
Bonnie H. Anderson
Chairman and Chief Executive Officer and Director
John L. Bishop
Lead Independent Director
Evan Jones
Director
Fred E. Cohen
Director
Karin Eastham
Director
Kevin K. Gordon
Director
Robert S. Epstein
Director
Tina S. Nova
Director

Shareholders

Name
Position
Bonnie H. Anderson
Chairman and Chief Executive Officer and Director
Keith Kennedy
Chief Operating Officer and Chief Financial Officer
Giulia C. Kennedy
Chief Scientific Officer and Chief Medical Officer
John Hanna
Chief Commercial Officer